徐希奇, 荆志成. 第六届世界肺高血压会议:聚焦肺高血压定义与诊断分类更新[J]. 协和医学杂志, 2018, 9(3): 197-201. DOI: 10.3969/j.issn.1674-9081.2018.03.002
引用本文: 徐希奇, 荆志成. 第六届世界肺高血压会议:聚焦肺高血压定义与诊断分类更新[J]. 协和医学杂志, 2018, 9(3): 197-201. DOI: 10.3969/j.issn.1674-9081.2018.03.002
Xi-qi XU, Zhi-cheng JING. The 6th World Symposium on Pulmonary Hypertension: Focus on Updates on Definition and Clinical Classification of Pulmonary Hypertension[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 197-201. DOI: 10.3969/j.issn.1674-9081.2018.03.002
Citation: Xi-qi XU, Zhi-cheng JING. The 6th World Symposium on Pulmonary Hypertension: Focus on Updates on Definition and Clinical Classification of Pulmonary Hypertension[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 197-201. DOI: 10.3969/j.issn.1674-9081.2018.03.002

第六届世界肺高血压会议:聚焦肺高血压定义与诊断分类更新

The 6th World Symposium on Pulmonary Hypertension: Focus on Updates on Definition and Clinical Classification of Pulmonary Hypertension

  • 摘要: 第六届世界肺高血压会议对肺高血压(pulmonary hypertension, PH)的定义和诊断分类进行了修订和更新。PH的血流动力学定义维持不变, 将毛细血管前性PH定义更新为:肺动脉平均压>20 mm Hg、肺动脉楔压 < 15 mm Hg且肺血管阻力> 3 WU。诊断分类更新包括:增加急性肺血管扩张试验阳性肺动脉高压(pulmonary arterial hypertension, PAH)亚类, 将甲基苯丙胺(冰毒)和达沙替尼致PAH作用由可能升级为肯定, 将肺静脉闭塞病/肺毛细血管瘤病由特殊的1'更新为PAH的一个亚类, 将脾切除术后和甲状腺疾病从PH诊断分类中移除等。本次PH定义和诊断分类更新将为临床实践提供重要指导意义。

     

    Abstract: The definition and clinical classification of pulmonary hypertension (PH) were updated in the 6th World Symposium on Pulmonary Hypertension (WSPH). The hemodynamic definition of PH keeps no change, but pre-capillary PH was redefined as mean pulmonary arterial pressure>20 mm Hg, pulmonary artery wedge pressure < 15 mm Hg and pulmonary vessel resistance>3 WU. The updated clinical classification included:pulmonary arterial hypertension(PAH) with vasoreactivity was added as a subclass of PAH; in drugs and toxins induced PAH, the role of methamphetamines and dasatinib was updated from likely to definite; pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis was changed from 1' to a subclass of PAH; splenectomy and thyroid diseases were withdrawn from the group 5 of PH, etc. These clinical practice updates will guide clinical practice better.

     

/

返回文章
返回